News
FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen
GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker th
